Curis reports on emavusertib progress in Q1 2024 By Investing.com

Curis, Inc. (CRIS) has provided an update in its Q1 2024 earnings call, focusing on the development of its drug emavusertib. The company is advancing the drug as a treatment for various cancers, including relapsed/refractory AML, primary CNS lymphoma, and as a triplet therapy for frontline AML patients. Curis announced that it will release top-line data for its TakeAim Leukemia study soon and plans to present at upcoming medical conferences. Despite a reported net loss of $11.9 million for the quarter, the company’s current funds are expected to support planned operations into 2025.

Key Takeaways

• Curis is advancing emavusertib across multiple cancer indications.
• Top-line data from the TakeAim Leukemia study for 25 new patients will be released next week.
• Detailed data presentations are scheduled for the ASCO and EHA medical conferences.
• The company reported a Q1 2024 net loss of $11.9 million but has sufficient funds to maintain planned operations into 2025.
• Emavusertib is showing promise in treating patients with resistance to FLT3 inhibition, with a response rate of 21%.
• Curis is exploring a potential partnership for further development and commercialization of emavusertib.

Company Outlook

• Curis aims to establish emavusertib as a new treatment benchmark.
• The company is hopeful for FDA registration based on single-agent activity and survival indications.

Bearish Highlights

• Curis reported a net loss of $11.9 million in Q1 2024.

Bullish Highlights

• Curis has $40.7 million in cash, cash equivalents, and investments.
• The company is seeing strong enrollment rates in clinical trials.

Misses

• There is a need for a companion diagnostic, which is being discussed for incorporation into a pivotal study.

Q&A Highlights

• CEO Jim Dentzer discussed the potential for a pivotal cohort in relapsed/refractory AML settings.
• Curis needs FDA guidance on whether to focus on FLT3 or spliceosome mutations in their study.
• Discussions with the FDA will also address the inclusion of patients with co-mutations in the studies.

In their Q1 2024 earnings call, Curis, Inc. detailed the progress of emavusertib, emphasizing its potential to redefine treatment benchmarks for certain cancer indications. The company is preparing for the release of important study data and presentations at high-profile medical conferences. Despite a quarterly loss, Curis’s financial position appears stable for the near future, with…